An unusual legal battle over a biotech startup's IPO plans escalated to another level on Valentine's Day, according to two ...
Sanofi & Teva's IBD drug duvakitug shows promise in Phase 2b with €1B sales potential by 2032, faces competition from Roivant ...
Amgen to invest $200M in new Hyderabad tech center through 2025, focusing on AI for drug development. Site opened Monday with ...
Phase 1b US study planned for 2026, as company competes with NS Pharma and Avidity Biosciences in exon 44 space ...
So far, only 22% of life sciences organizations have adopted AI at scale, yet 86% of healthcare and life sciences leaders ...
FDA denies Invivyd's EUA expansion for Pemgarda in Covid treatment while BioCryst reports positive Orladeyo data. AN2 changes endpoint, OS Therapies seeks partners & Eyenovia restructures.
Tang Capital's Concentra Biosciences offers to buy Acelyrin for $3/share, challenging planned Alumis merger. Concentra would ...
UnitedHealthcare offers voluntary buyouts to 30,000 employees due to low attrition and digital shift, COO Michael Baker tells ...
As he was testing new antivirals to halt a future pandemic, John Chodera encountered an unlikely set of new problems that ...
Spotlight Therapeutics, a startup with a bold vision for delivering CRISPR therapies into the body without the ...
Celia Witten, deputy director of the FDA's Center for Biologics Evaluation and Research, has left the FDA, adding to a wave ...
A pair of investors will acquire bluebird bio in a deal worth only $29 million upfront after the gene therapy maker ran out ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback